AVANOS MEDICAL, INC. 8-K

What Happened

• Avanos Medical, Inc. announced on March 6, 2026 that its Board increased the target value of the annual long-term incentive award available to CEO David C. Pacitti under the company’s 2021 Long Term Incentive Plan (as amended). The target was raised from $5,000,000 to $5,500,000, effective beginning in 2026. The company filed the related Form 8-K on March 12, 2026.

Key Details

• CEO: David C. Pacitti.
• Previous target annual LTIP value: $5,000,000.
• New target annual LTIP value: $5,500,000 (effective beginning in 2026).
• Authority: change made under the company’s 2021 Long Term Incentive Plan, as amended.
• Filing: Form 8-K reported by Avanos Medical on March 12, 2026.

Why It Matters

• This change increases the potential value of the CEO’s annual long-term incentive opportunity, which may affect future executive compensation expense and the size or structure of equity awards the company grants.
• The 8-K does not disclose specific grant amounts, timing, or performance conditions tied to awards — investors should watch future proxy filings or 8-Ks for details on actual grants, performance metrics, and any impact on dilution or reported compensation.